Free Trial

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis logo
$148.64 +1.88 (+1.28%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$148.60 -0.04 (-0.03%)
As of 04/17/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
11

Based on 12 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 1 has given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for ZTS.

Consensus Price Target

$214.40
44.24% Upside
According to the 12 analysts' twelve-month price targets for Zoetis, the average price target is $214.40. The highest price target for ZTS is $244.00, while the lowest price target for ZTS is $165.00. The average price target represents a forecasted upside of 44.24% from the current price of $148.64.
Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

Sign Up

ZTS Analyst Ratings Over Time

TypeCurrent Forecast
4/18/24 to 4/18/25
1 Month Ago
3/19/24 to 3/19/25
3 Months Ago
1/19/24 to 1/18/25
1 Year Ago
4/19/23 to 4/18/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$214.40$215.90$211.89$221.75
Forecasted Upside44.24% Upside31.84% Upside27.64% Upside44.83% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zoetis Stock vs. The Competition

TypeZoetisMedical CompaniesS&P 500
Consensus Rating Score
3.08
2.81
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside44.24% Upside21,674.42% Upside26.48% Upside
News Sentiment Rating
Positive News

See Recent ZTS News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/14/2025Stifel Nicolaus
4 of 5 stars
Jonathan Block
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$180.00 ➝ $165.00+9.87%
2/27/2025Piper Sandler
2 of 5 stars
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$200.00 ➝ $205.00+24.25%
2/14/2025Barclays
3 of 5 stars
Balaji Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$242.00 ➝ $244.00+52.72%
2/14/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$243.00 ➝ $238.00+49.95%
12/9/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$196.00+10.04%
12/2/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/2/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$215.00+22.68%
10/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$225.00 ➝ $230.00+20.70%
8/12/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Massaro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$220.00 ➝ $225.00+22.75%
8/9/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$230.00 ➝ $225.00+36.80%
5/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$223.00 ➝ $196.00+17.58%
12/19/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$230.00+16.03%
12/7/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$237.00+30.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:56 PM ET.


Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 15, 2025. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. has received multiple upgrades from analysts, with Piper Sandler raising their price target to $205.00, indicating strong confidence in the company's growth potential.
  • The stock currently trades at approximately $150.31, which may present a buying opportunity given the average price target of $214.40 set by analysts, suggesting significant upside potential.
  • With a consensus rating of "Buy" from ten analysts and two strong buy ratings, investor sentiment is largely positive, indicating confidence in the company's future performance.
  • Zoetis Inc. has a solid market capitalization of around $67.07 billion, reflecting its strong position in the animal health industry and providing stability for investors.
  • The company has demonstrated resilience with a P/E ratio of 27.48, which, while indicating a premium valuation, also suggests that investors are willing to pay for expected growth in earnings.

Zoetis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • Stifel Nicolaus recently lowered their price target from $180.00 to $165.00, which may indicate a more cautious outlook on the company's near-term performance.
  • Insider selling has been noted, with a director selling 1,210 shares, which could signal a lack of confidence in the stock's short-term prospects.
  • The stock has experienced volatility, with a 52-week range between $139.70 and $200.33, suggesting potential risks for investors looking for stability.
  • Zoetis Inc. has a debt-to-equity ratio of 1.09, indicating that the company has taken on a moderate level of debt, which could pose risks if market conditions change.
  • The recent average trading volume of 3,034,417 shares suggests that liquidity may be a concern, potentially impacting the ease of buying or selling shares without affecting the stock price significantly.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $214.40, with a high forecast of $244.00 and a low forecast of $165.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There is currently 1 hold rating, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZTS shares.

According to analysts, Zoetis's stock has a predicted upside of 44.24% based on their 12-month stock forecasts.

Zoetis has been rated by research analysts at Barclays, Morgan Stanley, Piper Sandler, and Stifel Nicolaus in the past 90 days.

Analysts like Zoetis more than other "medical" companies. The consensus rating for Zoetis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZTS compares to other companies.


This page (NYSE:ZTS) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners